Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 8/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | ALAD | P13716 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2557224 | 0.82 | PTPN2 (0.41) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2064339 | 0.76 | DAO (0.59) | DAOGPR35ALDH1A1KDM4EMAPT | |
| SCHEMBL899479 | 0.74 | GSK3B (0.61) | DAOGPR35ALDH1A1KDM4EMAPT | |
| SCHEMBL2064966 | 0.73 | DAO (0.41) | DAOGPR35ALDH1A1KDM4EMAPT | |
| SCHEMBL6305183 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL8935203 | 0.72 | GSK3B (0.59) | DAOGPR35ALDH1A1KDM4EMAPT | |
| Bromide SCHEMBL8935164 | 0.72 | GSK3B (0.59) | DAOGPR35ALDH1A1KDM4EMAPT | |
| SCHEMBL25365859 | 0.71 | DAO (0.43) | DAOGPR35ALDH1A1KDM4EMAPT | |
| SCHEMBL1529502 | 0.71 | DAO (0.63) | DAOGPR35ALDH1A1KDM4EMAPT | |
| SCHEMBL28891536 | 0.71 | DAO (0.43) | DAOGPR35ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-7485661-B2 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| EP-1534716-B1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-04-23 | — | — | EP | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2006-07-20 | — | — | US | disclosed |
| EP-1534716-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004007504-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | MAP2K2, MAP3K15, MAP3K5 | DAO 2287/4885GPR35 1563/4885ALDH1A1 3709/4885 |
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | DAO 1077/4885GPR35 904/4885ALDH1A1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.